Additionally, it is the first to examine its inhibitory effect on GSK-3β, offering new insights into its potential as an AD treatment, and in recent years, significant progress has been made in the medicinal chemistry of GSK-3β. The gene discussed is GSK3B; the disease is Alzheimer disease.